CVXL-0255
Immuno-inflammatory diseases (via inhibition of SYK and JAK enzymes)
Pre-clinicalActive
Key Facts
Indication
Immuno-inflammatory diseases (via inhibition of SYK and JAK enzymes)
Phase
Pre-clinical
Status
Active
Company
About Clevexel Pharma
Clevexel Pharma is a private, clinical-stage biotech company based in Paris, France, focusing on advancing novel therapeutic candidates to clinical proof-of-concept. The company leverages its expertise in drug development to identify and progress molecules with high potential, operating through a partnership-driven model. Its pipeline includes CVXL-0095 for reducing mucositis/dermatitis from cancer therapy and CVXL-0255, a dual SYK/JAK inhibitor for immuno-inflammatory conditions. Clevexel has been recognized as an innovative company by the Medicen Paris Region competitiveness cluster.
View full company profile